PrimeC, an experimental combination treatment for amyotrophic lateral sclerosis (ALS) being developed by NeuroSense Therapeutics, was well tolerated…
Articles by Marisa Wexler, MS
AMX0035 — Amylyx Pharmaceuticals’ experimental combination therapy for amyotrophic lateral sclerosis (ALS) now under review for approval in the U.S. —…
The levels of five small RNA molecules, called microRNAs, inside tiny vesicles in the blood of people with amyotrophic…
A treatment known as VPA-Li, a combination of lithium carbonate and valproic acid, may slow disease progression and improve quality…
In a reversal, an advisory committee of the U.S. Food and Drug Administration (FDA) now says that the current evidence…
Higher blood levels of antibodies against the viral protein HERV-K ENV are associated with a better survival rate and improved…
Altered forms of the SOD1 protein are found in the spinal cord nerve cells of people with all types of…
Treatment with gene therapy candidate SynCav1 delayed disease onset and extended survival in a mouse model of amyotrophic lateral sclerosis (ALS),…
Treatment with terazosin, a medication approved to treat high blood pressure and enlarged prostate, was found to protect motor neurons…
A mutation in the STMN2 gene that consists of an excessive repeat of two nucleotides, the building blocks of DNA, is not…